Status:
UNKNOWN
Metabolic Profile as a Predictor of No-reflow in Diabetic Patients
Lead Sponsor:
El Zahraa Gamal
Conditions:
Acute Myocardial Infarction (AMI)
Eligibility:
All Genders
Brief Summary
to find metabolic factors that correlate with the development of no-reflow phenomenon that may help prevent its occurrence
Detailed Description
Acute myocardial infarction (AMI) with its accompanying adverse sequelae is one of the most common causes of morbidity and mortality in the world . Although reperfusion techniques for ST- elevation m...
Eligibility Criteria
Inclusion
- diabetic patients with ST- elevation myocardial infarction (STEMI ) treated with primary Percutaneous Coronary Intervention ( PCI ) .
Exclusion
- diabetic patients with ST- elevation myocardial infarction (STEMI ) treated with primary Percutaneous Coronary Intervention ( PCI ) : but have
- (1) a history of an unprotected left main artery with severe liver and kidney diseases or coronary artery bypass grafting .
- (2) patients who had valvular disease or cardiomyopathy . (3) severe dissection, thromboembolism in other parts, or vasospasm; and known malignancy .
- (4) patients with contraindications for anticoagulant therapy, such as active visceral hemorrhage, hemorrhagic stroke, or ischemic stroke within half a year (including transient ischemic attack), or aortic dissection, or patients with hematological diseases complicated with coagulation disorders .
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04835207
Start Date
April 1 2021
End Date
April 1 2022
Last Update
April 8 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.